191 related articles for article (PubMed ID: 31796676)
1. Associations Between Microstructure, Amyloid, and Cognition in Amnestic Mild Cognitive Impairment and Dementia.
Reas ET; Hagler DJ; Kuperman JM; Wierenga CE; Galasko D; White NS; Dale AM; Banks SJ; McEvoy LK; Brewer JB
J Alzheimers Dis; 2020; 73(1):347-357. PubMed ID: 31796676
[TBL] [Abstract][Full Text] [Related]
2. Microstructural brain changes track cognitive decline in mild cognitive impairment.
Reas ET; Hagler DJ; White NS; Kuperman JM; Bartsch H; Wierenga CE; Galasko D; Brewer JB; Dale AM; McEvoy LK
Neuroimage Clin; 2018; 20():883-891. PubMed ID: 30290303
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer's disease.
Reas ET; Hagler DJ; White NS; Kuperman JM; Bartsch H; Cross K; Loi RQ; Balachandra AR; Meloy MJ; Wierenga CE; Galasko D; Brewer JB; Dale AM; McEvoy LK
Alzheimers Res Ther; 2017 Aug; 9(1):55. PubMed ID: 28764771
[TBL] [Abstract][Full Text] [Related]
4. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.
Selnes P; Aarsland D; Bjørnerud A; Gjerstad L; Wallin A; Hessen E; Reinvang I; Grambaite R; Auning E; Kjærvik VK; Due-Tønnessen P; Stenset V; Fladby T
J Alzheimers Dis; 2013; 33(3):723-36. PubMed ID: 23186987
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer's Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness.
Teipel SJ; Kuper-Smith JO; Bartels C; Brosseron F; Buchmann M; Buerger K; Catak C; Janowitz D; Dechent P; Dobisch L; Ertl-Wagner B; Fließbach K; Haynes JD; Heneka MT; Kilimann I; Laske C; Li S; Menne F; Metzger CD; Priller J; Pross V; Ramirez A; Scheffler K; Schneider A; Spottke A; Spruth EJ; Wagner M; Wiltfang J; Wolfsgruber S; Düzel E; Jessen F; Dyrba M;
J Alzheimers Dis; 2019; 72(2):455-465. PubMed ID: 31594223
[TBL] [Abstract][Full Text] [Related]
6. Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment.
Canuet L; Pusil S; López ME; Bajo R; Pineda-Pardo JÁ; Cuesta P; Gálvez G; Gaztelu JM; Lourido D; García-Ribas G; Maestú F
J Neurosci; 2015 Jul; 35(28):10325-30. PubMed ID: 26180207
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
[TBL] [Abstract][Full Text] [Related]
8. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.
d'Oleire Uquillas F; Jacobs HIL; Hanseeuw B; Marshall GA; Properzi M; Schultz AP; LaPoint MR; Johnson KA; Sperling RA; Vannini P
Neuroimage Clin; 2018; 17():388-396. PubMed ID: 29159051
[TBL] [Abstract][Full Text] [Related]
9. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
[TBL] [Abstract][Full Text] [Related]
10. Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease.
Spotorno N; Strandberg O; Vis G; Stomrud E; Nilsson M; Hansson O
Brain; 2023 Apr; 146(4):1602-1614. PubMed ID: 36130332
[TBL] [Abstract][Full Text] [Related]
11. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
12. Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.
Dang C; Harrington KD; Lim YY; Ames D; Hassenstab J; Laws SM; Yassi N; Hickey M; Rainey-Smith SR; Robertson J; Rowe CC; Sohrabi HR; Salvado O; Weinborn M; Villemagne VL; Masters CL; Maruff P;
Arch Clin Neuropsychol; 2019 Jul; 34(5):585-598. PubMed ID: 30272115
[TBL] [Abstract][Full Text] [Related]
13. Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer's disease: a longitudinal cohort study.
Van Hooren RWE; Riphagen JM; Jacobs HIL;
Alzheimers Res Ther; 2018 Aug; 10(1):88. PubMed ID: 30153858
[TBL] [Abstract][Full Text] [Related]
14. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.
Racine AM; Adluru N; Alexander AL; Christian BT; Okonkwo OC; Oh J; Cleary CA; Birdsill A; Hillmer AT; Murali D; Barnhart TE; Gallagher CL; Carlsson CM; Rowley HA; Dowling NM; Asthana S; Sager MA; Bendlin BB; Johnson SC
Neuroimage Clin; 2014; 4():604-14. PubMed ID: 24936411
[TBL] [Abstract][Full Text] [Related]
15. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.
Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE
JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732
[TBL] [Abstract][Full Text] [Related]
16. In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion.
Hessen E; Kirsebom BE; Eriksson CM; Eliassen CF; Nakling AE; Bråthen G; Waterloo KK; Aarsland D; Fladby T
J Alzheimers Dis; 2019; 67(2):715-723. PubMed ID: 30614807
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
18. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.
Pontecorvo MJ; Devous MD; Kennedy I; Navitsky M; Lu M; Galante N; Salloway S; Doraiswamy PM; Southekal S; Arora AK; McGeehan A; Lim NC; Xiong H; Truocchio SP; Joshi AD; Shcherbinin S; Teske B; Fleisher AS; Mintun MA
Brain; 2019 Jun; 142(6):1723-1735. PubMed ID: 31009046
[TBL] [Abstract][Full Text] [Related]
19. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
